CervoMed Inc. (NASDAQ:CRVO) saw its stock rise 20% Thursday after receiving a notice of allowance from the United States Patent and Trademark Office for a patent pertaining to the use of neflamapimod in treating dementia with Lewy bodies (DLB).
The allowed patent specifically covers treatment of DLB in patients who do not have substantial Alzheimer’s disease-like tau pathology, a subgroup commonly described as "pure DLB." According to the notice, intellectual property protection tied to this allowance is expected to extend into 2042 and could be lengthened further through patent term extension.
CervoMed is a clinical-stage biotechnology company focused on developing therapies for age-related brain disorders. The newly allowed patent is intended to protect the company’s strategy for targeting treatment to patients with pure DLB. In the company’s approach, pure DLB can be identified by either plasma pTau levels or by brain imaging, as reflected in the scope of the allowed intellectual property.
The regulatory and clinical landscape for DLB remains notable in that there are currently no approved treatments for the condition in the United States or the European Union.
Summary
The USPTO’s notice of allowance for a patent on neflamapimod use in pure DLB patients coincided with a 20% rise in CervoMed’s share price. The patent is expected to provide exclusivity into 2042, with possible extension, and aims to protect the company’s biomarker-driven patient selection strategy. CervoMed remains a clinical-stage company developing therapies for age-related brain disorders, and there are no approved DLB treatments in the U.S. or EU.
Key points
- CervoMed shares advanced 20% after the USPTO issued a notice of allowance for a patent covering neflamapimod in DLB patients without substantial Alzheimer’s tau pathology.
- The allowed patent is expected to provide protection into 2042, with potential for patent term extension.
- The patent underpins a strategy to treat "pure DLB," identified via plasma pTau measurements or brain imaging - relevant to the biotech and pharmaceutical sectors, as well as healthcare investors monitoring neurodegenerative disease pipelines.
Risks and uncertainties
- The ultimate duration of protection may depend on patent term extension, an outcome referenced as possible but not guaranteed - a point of uncertainty for intellectual property planning.
- CervoMed is described as a clinical-stage company, which implies its programs, including neflamapimod in DLB, remain developmental and are not yet approved therapies.
- There are currently no approved treatments for DLB in the U.S. or EU, highlighting the regulatory and commercial path that would need to be navigated before any therapy could reach patients.